Related Experiment Videos
Fulminant Mycoplasma pneumoniae pneumonia
1Division of Pulmonary Sciences, University of Colorado Health Sciences Center, Denver 80262, USA.
The Western Journal of Medicine
|February 1, 1995
Summary
Fulminant pneumonia from Mycoplasma pneumoniae is rare but severe, often affecting young males. Enhanced immune responses may drive severe cases, with corticosteroids potentially aiding recovery.
Area of Science:
- Pulmonology
- Infectious Diseases
- Immunology
Background:
- Mycoplasma pneumoniae infections are common, but severe, fulminant pneumonia is rare.
- This study reviews literature on fatal or respiratory failure-inducing M. pneumoniae pneumonia cases.
Observation:
- Fulminant cases disproportionately affect young, healthy adult males, and possibly smokers.
- Histopathology reveals small airways disease, including cellular bronchiolitis and bronchiolitis obliterans.
Findings:
- An enhanced host cellular immune response is hypothesized to cause severe disease.
- Pulmonary thromboembolism is notably increased in fatal cases.
Implications:
- Corticosteroids may benefit patients experiencing respiratory failure.
- Understanding host factors is crucial for managing severe Mycoplasma pneumoniae pneumonia.